Zinger Key Points
- Analyst Manuel Navas projects Burke & Herbert will achieve 8% loan growth in 2025 and strong mid-single-digit growth long-term.
- With significant repricing opportunities, the core net interest margin (NIM) is expected to expand amid upcoming Fed rate cuts.
DA Davidson analyst Manuel Navas initiated coverage on Burke & Herbert Financial Services BHRB with a Buy rating and price forecast of $76.
According to the analyst, the “hidden gem” is characterized by its “underappreciated” earnings potential and a lack of attention, leading to an appealing valuation that should benefit DMV footprint.
Navas notes that EPS growth is expected to be strong throughout the forecast period, with return expectations exceeding peers.
The projected 1.45% ROA and 16.5% ROTCE for 2025 should enhance the valuation, indicating a potential upside.
The analyst forecasts the company will achieve above-peer loan growth of 8% in 2025, with strong mid-single-digit growth expected over the long term.
Also Read: Goldman Sachs’ Q3 Report Impresses Analysts With Strong Investment Banking, Trading Revenues
The analyst notes that pipelines are robust due to competitors pulling back, with long-term growth expected in the mid-single digits (4%-6%). Navas projects 2% annualized loan growth in the second half of 2024, and 8% growth in 2025, aligning with the company’s conservative target of 8%-10%.
The analyst highlights that there are considerable repricing opportunities on the funding side, which will support the core net interest margin (NIM) amid rate cuts.
This includes $400 million in brokered CDs at over 5% and around $1 billion in a T-fund deposit product expected to reprice quickly. With an anticipated 50 basis points more in Fed rate cuts this year, totaling a -100 basis point impact for both 2024 and 2025, the projected reported NIM for 2024 and 2025 is 3.92% and 4.17%, respectively, along with an expanding core NIM.
Price Action: BHRB shares are trading higher by 4.3% to $63.73 at last check Wednesday.
Image via Unsplash
Read Next:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.